Nepuvibart (ZRC3308-B10) is a monoclonal antibody (mAb) (IgG1 type) targeting SARS-CoV-2. Nepuvibart shows good binding affinity to a noncompetitive epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart may be utilized in combination with ZRC3308-A7 at a 1:1 ratio and is effective for the prevention of COVID-19 and for early-stage COVID-19 that has not yet developed into severe disease.

Physicochemical Properties

CAS #	2640224-48-0
Appearance	Typically exists as solid at room temperature
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	SARS-CoV-2[1].
ln Vitro	Nepuvibart (ZRC3308-B10; 0-56 ng/mL) in a 1:1 ratio with ZRC3308-B10 exhibits virus-neutralizing action in the VeroE6/Vero CCL81 (SARS-CoV-2 infection model) [1]. When coupled in a 1:1 ratio (AY.1) with ZRC3308-A7, nepuvibart neutralizes SARS-CoV-2 strains B.1B.1.7, B.1.351, B.1.617.2, and B.1.617.2 in vitro[1].Nepuvibart attaches itself to the SARS-CoV-2 S1 protein's RBD [1].
ln Vivo	When paired with ZRC3308-A7 (1:1 combination)-2 infection, nemuvibart (ZRC3308-B10; 0.5, 2.5, and 25 mg/kg; given 48 hours prior to SARS-CoV-2 infection) effectively prevents SARS-CoV in Syrian hamsters[1]. Nepuvibart (0.5, 2.5, 25 mg/kg; ip; single) Serum concentrations in Syrian hamsters don't significantly decrease over a period of up to seven days [1].
Cell Assay	Cell Viability Assay[1] Cell Types: VeroE6/Vero CCL81 cells (SARS-CoV-2 infection model) Tested Concentrations: 0-5× 105 ng/mL (in combination with ZRC3308-A7) Incubation Duration: 72 h Experimental Results: demonstrated potent neutralization activity with an IC50 of 0.1283 ng/mL.
Animal Protocol	Animal/Disease Models: Female syrian hamster (7 to 10weeks old; SARS-CoV-2 infection model)[1]. Doses: 0.5, 2.5, 25 mg/kg Route of Administration: intraperitoneal (ip)injection; 48 h prior to the SARS-CoV-2 infection Experimental Results: Prevented SARS-CoV-2 infection when in combination with ZRC3308-A7.
References	[1]. ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection. Viruses. 2021 Dec 3;13(12):2424.

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)